Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Dual transfusion independence and spleen volume reduction is associated with overall survival in patients with myelofibrosis treated with momelotinib: Post hoc analyses of SIMPLIFY-1 and MOMENTUM

Francesca Palandri, Nicolaas Schaap, Jérôme Rey, Nikolas Von Bubnoff, Andreas Reiter, Juan Carlos Hernandez Boluda, Timothy Devos, Bethan Psaila, Donal McLornan, Catherine Ellis, Fulya Sen Nikitas, Shiyuan Zhang, Jessica Lim, Dwaipayan Patnaik, Stephen Oh

Blood (2025) 146 (Supplement 1): 2023.

https://doi.org/10.1182/blood-2025-2023

Published: 2025

Journal Articles

Impact of new or worsening anemia and thrombocytopenia on clinical outcomes in JAK inhibitor–naive myelofibrosis patients treated with ruxolitinib

Vikas Gupta, Francesca Palandri, Jean-Jacques Kiladjian, Bethan Psaila, Bella Vo, Jessica Lim, Fulya Sen Nikitas, Shiyuan Zhang, Tom (sizhu) Liu, Catherine Ellis, Jasmine Sahni, Dwaipayan Patnaik, Stephen Oh, Ruben Mesa

Blood (2025) 146 (Supplement 1): 3809.

https://doi.org/10.1182/blood-2025-3809

Published: 2025

Journal Articles

Interim analysis of promise, a clinical study combining the BET inhibitor OPN-2853 with ruxolitinib in patients with advanced myelofibrosis experiencing an inadequate response to ruxolitinib

Blood (2025) 146 (Supplement 1): 3794.

https://doi.org/10.1182/blood-2025-3794

Published: 2025

Journal Articles

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Blood (2025) 146 (Supplement 1): 484.

https://doi.org/10.1182/blood-2025-484

Published: 2025

Journal Articles

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Blood (2025) 146 (Supplement 1): 1024.

https://doi.org/10.1182/blood-2025-1024

Published: 2025

Journal Articles

Molecular characterization of patients (pts) with myeloproliferative neoplasms treated with INCA033989 demonstrates selective targeting of CALR mutant hematopoietic cells

Bethan Psaila, Jyoti Nangalia, Jason Gotlib, Claire Harrison, John Mascarenhas, Erin Crowgey, Betty Lamothe, Chenwei Tian, Evan Braunstein, Steffen Koschmieder

Blood (2025) 146 (Supplement 1): 71.

https://doi.org/10.1182/blood-2025-71

Published: 2025

Journal Articles

Genome editing for treatment of JAK2 V617F-driven myeloproliferative neoplasms

Roman Doll, Yuqi Shen, Zoë Wong, Ramy Slama, Maria Greco, Lai Cheng, Eleni Louka, Weijiao Zhang, Yavor Bozhilov, Joseph Hamley, Adam Wilkinson, Bethan Psaila, Adam Mead, James Davies

Blood (2025) 146 (Supplement 1): 68.

https://doi.org/10.1182/blood-2025-68

Published: 2025

Journal Articles

INCA033989: the first shot on goal for MPNs?

Camelia Benlabiod, Bethan Psaila

Blood (2024) 144 (22): 2278–2279.

https://doi.org/10.1182/blood.2024026811

Published: 2024

Journal Articles

Mapping the Human Bone Marrow in Myeloproliferative Neoplasia Using Spatial Transcriptomics

Rosalin Cooper, Emily Thomas, Dawood Muhammad, Carlo Pescia, Anna Sozanska, Oliver McCallion, Hosuk Ryou, Renuka Teague, Alan King Lun Liu, Joanna Hester, Fadi Issa, Bethan Psaila, Adam J Mead, Jens Rittscher, Dan Woodcock, Daniel Royston

Blood (2024) 144 (Supplement 1): 876.

https://doi.org/10.1182/blood-2024-205266

Published: 2024

Journal Articles

Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms and Evaluation in the Relevant Human Tissue Environment

Alexandros Rampotas, Zoe Wong, Isaac Gannon, Camelia Benlabiod, Yuqi Shen, Charlotte Brierley, Aude-Anais Olijnik, Saif Khan, Nawshad Hayder, Gordon Weng-Kit Cheung, Marina Mitsikakou, Manuel Rodriguez-Justo, Abdullah O Khan, Adam J Mead, Jonathan Lambert, Claire Roddie, Bethan Psaila, Martin A Pule

Blood (2024) 144 (Supplement 1): 871.

https://doi.org/10.1182/blood-2024-204953

Published: 2024

Journal Articles

Tolerance of Whole Genome Duplication in Megakaryocytes, and Consequences for Their Genome Integrity

Antonio Rodriguez-Romera, Rong Li, Nah-Young Shin, Sally-Ann Clark, Assunta Adamo, Affaf Aliouat, Abdullah Khan, Aude-Anais Olijnik, Jill Brown, Lucia Sommerova, Natalie Jooss, Akiko Shimamura, Xin Lu, Guanlin Wang, Stefan N. Constantinescu, Ketan Patel, Adam J Mead, Alan B. Cantor, Bethan Psaila

Blood (2024) 144 (Supplement 1): 421.

https://doi.org/10.1182/blood-2024-203123

Published: 2024

Journal Articles

Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort

Blood (2024) 144 (Supplement 1): 1804.

https://doi.org/10.1182/blood-2024-207251

Published: 2024

Journal Articles

Interim Analysis of Promise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib

Adam J Mead, Brian J P Huntly, Bethan Psaila, Claire Harrison, Rebecca Boucher, Jiayi Wang, Rebecca Collings, Zsofia Nagy, Rebecca Record

Blood (2024) 144 (Supplement 1): 3186.

https://doi.org/10.1182/blood-2024-205105

Published: 2024

Journal Articles

RUX-AZA Response in AP/BP-MPN Is Driven By Release of the Differentiation Block in Mutant HSPCs: A Single-Cell Multi-Omic Analysis of Responders on the Phase Ib Phazar Study

Blood (2024) 144 (Supplement 1): 3146.

https://doi.org/10.1182/blood-2024-204818

Published: 2024

Journal Articles

The Fetal Specific Gene LIN28B Is Essential for Human Fetal B-Lymphopoiesis and Initiation of KMT2A-AFF1+ Infant Acute Lymphoblastic Leukemia

Rebecca E Ling, Thomas Jackson, Natalina Elliott, Joe W Cross, Lucy Hamer, Arundhati S Wuppalapati, Alastair L Smith, Catherine M Chahrour, Okan Sevim, Deena Iskander, Guanlin Wang, Sorcha I O'Byrne, Siobhan Rice, Joe R Harman, Bethan Psaila, Rhys G Morgan, Irene Roberts, Thomas A Milne, Anindita Roy

Blood (2024) 144 (Supplement 1): 199.

https://doi.org/10.1182/blood-2024-198819

Published: 2024

Journal Articles

Amplification of Von Willebrand Factor-Positive CALR mut Disease-Initiating Hematopoietic Stem Cells Is Associated to the Activation of the PERK/EiF2a Branch of Unfolded Protein Response

Camelia Benlabiod, Gurvan Hermange, Laetitia Borderon, Quentin Blampey, Maxime Evrard, Antonio Rodriguez Romera, Stéphanie G. Moreno, Nathalie Gault, Philippe Rameau, Cyril Catelain, Elodie Rosa, Bethan Psaila, Claus Nerlov, Sten Eirik Waelgaard Jacobsen, William Vainchenker, Hana Raslova, Paul-Henry Cournède, Isabelle Plo, Caroline Marty

Blood (2024) 144 (Supplement 1): 752.

https://doi.org/10.1182/blood-2024-205477

Published: 2024

Journal Articles

Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib

Blood (2024) 143 (2): 178–182.

https://doi.org/10.1182/blood.2023022345

Published: 2024

Includes: Supplemental data

Journal Articles

Cooperation between SF3B1 and JAK2 V617F Mutations Accelerates Fibrotic Progression in Myeloproliferative Neoplasms By Enhancing STAT1 Signaling

Jennifer O Sullivan, Sean Wen, Affaf Aliouat, Alba Rodriguez-Meira, Sally-Ann Clark, Neil Ashley, Amy Wood, Ramy Slama, Guanlin Wang, Angela Hamblin, Lauren Murphy, Christina Simoglou Karali, Charlotte K Brierley, Adam P Cribbs, Aimee Paterson, Claire N Harrison, Bethan Psaila, Adam J Mead

Blood (2023) 142 (Supplement 1): 861.

https://doi.org/10.1182/blood-2023-185118

Published: 2023

Journal Articles

Platelets Sequester Extracellular DNA, Capturing Tumour-Derived and Free Fetal DNA

Blood (2023) 142 (Supplement 1): 277.

https://doi.org/10.1182/blood-2023-182697

Published: 2023

Journal Articles

Promise: Investigation into the Combination of a Potent Beti with Ruxolitinib in Patients with High or Intermediate-2 Risk Myelofibrosis Not Receiving an Adequate Response with Ruxolitinib Alone

Adam J Mead, Claire N Harrison, Brian Huntly, Bethan Psaila, Rebecca Boucher, Sonia Fox, Louise Hopkins, Joseph Rogers, Charlotte Gaskell, Amit Patel

Blood (2023) 142 (Supplement 1): 6442.

https://doi.org/10.1182/blood-2023-185798

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Dual transfusion independence and spleen volume reduction is associated with overall survival in patients with myelofibrosis treated with momelotinib: Post hoc analyses of SIMPLIFY-1 and MOMENTUM

Impact of new or worsening anemia and thrombocytopenia on clinical outcomes in JAK inhibitor–naive myelofibrosis patients treated with ruxolitinib

Interim analysis of promise, a clinical study combining the BET inhibitor OPN-2853 with ruxolitinib in patients with advanced myelofibrosis experiencing an inadequate response to ruxolitinib

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Molecular characterization of patients (pts) with myeloproliferative neoplasms treated with INCA033989 demonstrates selective targeting of CALR mutant hematopoietic cells

Genome editing for treatment of JAK2 V617F-driven myeloproliferative neoplasms

INCA033989: the first shot on goal for MPNs?

Mapping the Human Bone Marrow in Myeloproliferative Neoplasia Using Spatial Transcriptomics

Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms and Evaluation in the Relevant Human Tissue Environment

Tolerance of Whole Genome Duplication in Megakaryocytes, and Consequences for Their Genome Integrity

Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort

Interim Analysis of Promise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib

RUX-AZA Response in AP/BP-MPN Is Driven By Release of the Differentiation Block in Mutant HSPCs: A Single-Cell Multi-Omic Analysis of Responders on the Phase Ib Phazar Study

The Fetal Specific Gene LIN28B Is Essential for Human Fetal B-Lymphopoiesis and Initiation of KMT2A-AFF1+ Infant Acute Lymphoblastic Leukemia

Amplification of Von Willebrand Factor-Positive CALR mut Disease-Initiating Hematopoietic Stem Cells Is Associated to the Activation of the PERK/EiF2a Branch of Unfolded Protein Response

Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib

Cooperation between SF3B1 and JAK2 V617F Mutations Accelerates Fibrotic Progression in Myeloproliferative Neoplasms By Enhancing STAT1 Signaling

Platelets Sequester Extracellular DNA, Capturing Tumour-Derived and Free Fetal DNA

Promise: Investigation into the Combination of a Potent Beti with Ruxolitinib in Patients with High or Intermediate-2 Risk Myelofibrosis Not Receiving an Adequate Response with Ruxolitinib Alone

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only